Abbvie Says Phase 3 Studies Show Continued Repigmentation With Rinvoq Through Week 76
Oct 1 (Reuters) - AbbVie Inc. ABBV.N:
ABBVIE - PHASE 3 STUDIES SHOW CONTINUED REPIGMENTATION WITH RINVOQ THROUGH WEEK 76
ABBVIE - RINVOQ PLUS NB-UVB SHOWS HIGHER REPIGMENTATION THAN RINVOQ ALONE